BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1045 related articles for article (PubMed ID: 20945361)

  • 1. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in capillary electrophoresis-based proteomic techniques for biomarker discovery.
    Fang X; Balgley BM; Lee CS
    Electrophoresis; 2009 Dec; 30(23):3998-4007. PubMed ID: 19960464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proteomic advantage: label-free quantification of proteins expressed in bovine milk during experimentally induced coliform mastitis.
    Boehmer JL; DeGrasse JA; McFarland MA; Tall EA; Shefcheck KJ; Ward JL; Bannerman DD
    Vet Immunol Immunopathol; 2010 Dec; 138(4):252-66. PubMed ID: 21067814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry.
    Matta A; DeSouza LV; Shukla NK; Gupta SD; Ralhan R; Siu KW
    J Proteome Res; 2008 May; 7(5):2078-87. PubMed ID: 18407684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis.
    Bouchal P; Roumeliotis T; Hrstka R; Nenutil R; Vojtesek B; Garbis SD
    J Proteome Res; 2009 Jan; 8(1):362-73. PubMed ID: 19053527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
    Fredolini C; Liotta LA; Petricoin EF
    Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer proteomics: from biomarker discovery to signal pathway profiling.
    Bichsel VE; Liotta LA; Petricoin EF
    Cancer J; 2001; 7(1):69-78. PubMed ID: 11269650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head and neck cancer: proteomic advances and biomarker achievements.
    Rezende TM; de Souza Freire M; Franco OL
    Cancer; 2010 Nov; 116(21):4914-25. PubMed ID: 20665484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Casting light on molecular events underlying anti-cancer drug treatment: what can be seen from the proteomics point of view?
    Kraljevic S; Sedic M; Scott M; Gehrig P; Schlapbach R; Pavelic K
    Cancer Treat Rev; 2006 Dec; 32(8):619-29. PubMed ID: 17069979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.
    Bharti A; Ma PC; Salgia R
    Mass Spectrom Rev; 2007; 26(3):451-66. PubMed ID: 17407130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-analytic saliva processing affect proteomic results and biomarker screening of head and neck squamous carcinoma.
    Ohshiro K; Rosenthal DI; Koomen JM; Streckfus CF; Chambers M; Kobayashi R; El-Naggar AK
    Int J Oncol; 2007 Mar; 30(3):743-9. PubMed ID: 17273777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic analysis of protein expression in human tonsillar cancer: differentially expressed proteins characterize human tonsillar cancer.
    Roblick UJ; Bader FG; Hammarstedt L; Habermann JK; Hellman U; Becker S; Sundmacker A; Gemoll T; Zimmermann K; Auer G; Munck-Wikland E
    Acta Oncol; 2008; 47(8):1493-501. PubMed ID: 18759147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery.
    Hu S; Yen Y; Ann D; Wong DT
    Drug Discov Today; 2007 Nov; 12(21-22):911-6. PubMed ID: 17993408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of proteins secreted by head and neck cancer cell lines using LC-MS/MS: Strategy for discovery of candidate serological biomarkers.
    Ralhan R; Masui O; Desouza LV; Matta A; Macha M; Siu KW
    Proteomics; 2011 Jun; 11(12):2363-76. PubMed ID: 21598386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced proteomic technologies for cancer biomarker discovery.
    Wong SC; Chan CM; Ma BB; Lam MY; Choi GC; Au TC; Chan AS; Chan AT
    Expert Rev Proteomics; 2009 Apr; 6(2):123-34. PubMed ID: 19385940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomics for the identification of new prostate cancer biomarkers.
    Ornstein DK; Tyson DR
    Urol Oncol; 2006; 24(3):231-6. PubMed ID: 16678055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomics in prostate cancer biomarker discovery.
    Larkin SE; Zeidan B; Taylor MG; Bickers B; Al-Ruwaili J; Aukim-Hastie C; Townsend PA
    Expert Rev Proteomics; 2010 Feb; 7(1):93-102. PubMed ID: 20121479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel tumor marker discovery of gastrointestinal cancers using various proteomic approaches].
    Tomonaga T; Nomura F
    Rinsho Byori; 2007 Jan; 55(1):63-8. PubMed ID: 17319493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in clinical proteomics using mass spectrometry.
    Dowling P; Meleady P; Henry M; Clynes M
    Bioanalysis; 2010 Sep; 2(9):1609-15. PubMed ID: 21083289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.